Business Context and Reporting Period
This Form 8-K is filed by Pro-Pharmaceuticals, Inc. (not Galectin Therapeutics Inc.) for the reporting period of November 4, 2003. The company is incorporated in Nevada and operates in the pharmaceutical sector, focusing on carbohydrate drug targeting and delivery platforms.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on regulatory and intellectual property events rather than financial performance.
Material Changes
The primary material event reported is the issuance of two U.S. patents by the U.S. Patent and Trademark Office covering the company's core technology:
- November 4, 2003: Patent No. 6,642,205 titled "Methods and Compositions for Reducing Side Effects in Chemotherapeutic Treatments."
- November 11, 2003: Patent No. 6,645,946 titled "Delivery of a Therapeutic Agent in a Formulation for Reduced Toxicity."
Guidance, Outlook, and Risks
The filing contains no financial guidance, forward-looking outlook, or specific risk factors beyond the general context of patent protection. The document serves as a Regulation FD disclosure regarding the patent grants and includes a press release dated November 13, 2003, as an exhibit.
Investor Verification Checklist
- Verify the registrant name is Pro-Pharmaceuticals, Inc. and not Galectin Therapeutics Inc.
- Confirm the validity and scope of U.S. Patents 6,642,205 and 6,645,946.
- Review the attached press release (Exhibit 99.1) for additional commercial implications of the patents.
- Check subsequent filings for financial data, as this 8-K contains none.